This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Why Is Biogen Inc. (BIIB) Up 8.2% Since Last Earnings Report?
by Zacks Equity Research
Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Novartis (NVS) Set to Advance Malaria Drug Into Phase III
by Zacks Equity Research
Novartis (NVS) plans to advance ganaplacide/lumefantrine into a phase III study for the treatment of patients with acute uncomplicated malaria due to Plasmodium falciparum.
BIIB or RGEN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
BIIB vs. RGEN: Which Stock Is the Better Value Option?
Regeneron's (REGN) Libtayo Gets EC Nod for Cervical Cancer
by Zacks Equity Research
Regeneron (REGN) gets EC's approval for the label expansion of PD-1 inhibitor Libtayo for the treatment of adult patients with recurrent or metastatic cervical cancer.
Is AMN Healthcare Services (AMN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how AMN Healthcare Services (AMN) and Biogen Inc. (BIIB) have performed compared to their sector so far this year.
Novartis (NVS) Reportedly Looking to Sell Its Business Units
by Zacks Equity Research
Per a Bloomberg report, Novartis (NVS) is considering the sale of its ophthalmology and respiratory franchises.
Is Biogen (BIIB) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Ionis (IONS) Inks Deal to Develop Precision Genetic Medicines
by Zacks Equity Research
Ionis (IONS) inks collaboration deal with the gene editing company, Metagenomi, to expand the former's capabilities in delivering precision genetic medicines.
Roche (RHHBY) AD Study Failure Puts Spotlight on BIIB & Others
by Zacks Equity Research
Roche's (RHHBY) gantenerumab study for early Alzheimer's disease (AD) fails and puts focus on other companies like BIIB, LLY and PRTA.
Ionis (IONS) Q3 Earnings & Sales Beat Estimates, Stock Up
by Zacks Equity Research
Ionis (IONS) incurs a narrower-than-expected loss in Q3. Its sales also beat estimates.
How Are Biotech ETFs Reacting to Q3 Earnings Releases?
by Sanghamitra Saha
Biotech earnings have come in upbeat in the third quarter.
BIIB vs. RGEN: Which Stock Is the Better Value Option?
by Zacks Equity Research
BIIB vs. RGEN: Which Stock Is the Better Value Option?
Denali (DNLI) Lags Q3 Earnings Estimates, Pipeline in Focus
by Zacks Equity Research
Denali (DNLI) posts a wider Q3 loss. Collaboration revenues decline year over year.
The Zacks Analyst Blog Highlights Bank of America, AT&T, Lockheed Martin, The Progressive and Biogen
by Zacks Equity Research
Bank of America, AT&T, Lockheed Martin, The Progressive and Biogen are part of the Zacks top Analyst Blog.
Top Stock Reports for Bank of America, AT&T US & Lockheed Martin
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Bank of America Corporation (BAC), AT&T Inc. (T) and Lockheed Martin Corporation (LMT).
AbbVie (ABBV) Beats on Q3 Earnings, Lags Sales, Narrows '22 View
by Zacks Equity Research
AbbVie's earnings (ABBV) beat estimates for third-quarter 2022, while sales miss the same. Shares drop in pre-market trading after it narrows down its full-year earnings guidance.
Biotech Stock Roundup: BIIB & BMY's Q3 Earnings, TCDA Down on Study Update
by Zacks Equity Research
Earnings updates from BIIB and BMY are the key highlights from the biotech sector during the past week.
Biogen (BIIB) Beats on Q3 Earnings & Sales, Raises 2022 Outlook
by Zacks Equity Research
Biogen (BIIB) beats third-quarter estimates for earnings and sales. Stock rises in pre-market as management raises the company's full-year 2022 financial guidance.
Biogen Inc. (BIIB) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Biogen Inc. (BIIB) delivered earnings and revenue surprises of 15.50% and 1.60%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Biogen (BIIB) to Report Q3 Earnings: Here's What to Expect
by Zacks Equity Research
Biogen's (BIIB) sales in the third quarter are likely to have been hurt by lower sales of Tecfidera and Spinraza.
Biotech Stock Roundup: NERV, RLMD Down on Updates, MRNA, NVAX's News & More
by Zacks Equity Research
Regulatory and pipeline updates from NERV and RLMD are the key highlights from the biotech sector during the past week.
BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biogen's (BIIB) FDA Filing for ALS Drug Gets 3 Months Extension
by Zacks Equity Research
The FDA extends the review period for Biogen's (BIIB) NDA for tofersen in SOD1-ALS. This extension is due to BIIB's submission of additional data, constituting a major amendment to the earlier filing.
Biogen Inc. (BIIB) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Biogen Inc. (BIIB) closed at $269.55 in the latest trading session, marking a +1.86% move from the prior day.
J&J (JNJ) to Start Q3 Earnings Season for Pharma Sector
by Zacks Equity Research
J&J's (JNJ) Pharma segment is expected to have performed above the market. In the MedTech segment, sales in the second half are expected to have been better than the first.